Detection of human papillomavirus E6/E7 mRNA in women with high-risk HPV types 16, 18, 31, 33 and 45 which are associated with the development of human cervical cancer

Purpose of investigation: The aim of our study was to increase the clinical meaningfulness of the virological data through mRNA E6/E7 oncoprotein identification, and to find a correlation between codon 72 polymorphism of the p53 gene and integration of HPV in host cell genomes. Methods: We analyzed 80 cervical samples from women with HPV DNA types 16, 18, 31, 33 and 45. Transcripts of HPV were detected by the NucliSense EasyQ HPV assay and genotyping of the TP53 polymorphism was conducted using a TaqMan assay. Results: Twenty percent of 80 tested samples were positive for mRNA Papillomavirus. The frequency of Arg/Pro heterozygotes in controls was over-represented compared with mRNA positive samples while there were no significant differences in the distribution of Pro/Pro and Arg/Arg alleles. Conclusion: The introduction of HPV mRNA testing in clinical analysis improved diagnostic accuracy of HPV infections. Our data suggest that a structural difference at codon 72 of the p53 gene may not be a sufficient risk factor for cervical carcinogenesis.

HR-HPV; E6/E7 mRNA; p53 polymorphisms; Cervical cancer

[1] Putral L.N., Bywater M.J., Gu W., Saunders N.A., Gabrielli B.G., Leggatt G.R., McMillan N.A.: “RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin”. Mol. Pharmacol., 2005, 68, 1311.

[2] Doorbar J.: “Molecular biology of human papillomavirus infection and cervical cancer”. Clin. Sci, 2006, 110, 525.

[3] Muñoz N., Bosch F.X., Castellsagué X., Diaz M., de Sanjose S., Hammouda D. et al.: “Against which human papillomavirus types shall we vaccinate and screen? The international perspective”. Int.

J. Cancer, 2004, 111, 278.

[4] Choo K.B., Pan C.C., Han S.H.: “Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames”. Virology, 1987, 161, 259.

[5] Romanczuk H., Howley P.M.: “Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity”. Proc. Natl. Acad. Sci USA, 1992, 89, 3159.

[6] Furumoto H., Irahara M.: “Human papilloma virus (HPV) and cervical cancer”. J. Med. Invest., 2002, 49, 124.

[7] Duensing S., Munger K.: “Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins”. Int. J. Cancer, 2004, 109, 157.

[8] Finzer P., Aguilar-Lemarroy A., Rosl F.: “The role of human papillomavirus oncoproteins E6 and E7 in apoptosis”. Cancer Lett., 2002, 188, 15.

[9] Longworth M.S., Laimins L.A.: “Pathogenesis of human papillomaviruses in differentiating epithelia”. Microbiol. Mol. Biol. Rev., 2004, 68, 362.

[10] Zur Hausen H.: “Papillomaviruses and cancer: from basic studies to clinical application”. Nat. Rev. Cancer, 2002, 2, 342.

[11] Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.: “The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53”. Cell, 1990, 63, 1129.

[12] Boyer S.N., Wazer D.E., Band V.: “E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway”. Cancer Res., 1996, 56, 4620.

[13] Matlashewski G.J., Tuck S., Pirn D., Lamb P., Schneider J., Crawford L.V: “Primary structure polymorphism at amino acid residue 72 of human p53”. Mol. Cell. Biol., 1987, 7, 961.

[14] Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G.: “Two polymorphic variants of wild-type p53 differ biochemically and biologically”. Mol. Cell. Biol., 1999, 19, 1092.

[15] Pim D., Banks L.: “p53 polymorphic variants at codon 72 exert different effects on cell cycle progression”. Int. J. Cancer, 2004, 108, 196.

[16] Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F. et al.: “Role of a p53 polymorphism in the development of human papillomavirus-associated cancer”. Nature, 1998, 393, 229.

[17] Helland A., Langerod A., Johnsen H., Olsen A.O., Skovlund E., Borresen-Dale A.: “p53 polymorphism and risk of cervical cancer”. Nature, 1998, 396, 530.

[18] Scheckenbach K., Lieven O., Gotte K., Bockmuhl U., Zotz R., Bier H. et al.: “p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck”. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1805.

[19] Muñoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsagué X., Shah K.V. et al.: “Epidemiological classification of HPV types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[20] Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[21] Gentile V., Vicini P., Giacomelli L.., Cardillo M.R., Pierangeli A., Degener A.M.: “Detection of human papillomavirus DNA, p53 and ki67 expression in penile carcinomas”. Int. J. Immunopathol. Pharmacol., 2006, 19, 209.

[22] Keegana H., McInerneya J., Pilkington L., Gronn P., Silva I., Karlsen F. et al.: “Comparison of HPV detection technologies: Hybrid capture 2, PreTect™ HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens”. J. Virol. Meth., 2009, 155, 61.

[23] Snijders P.J.F., Steenbergen R.D.M., Heideman D.A.M., Meijer C. J.L.M.: “HPV-mediated cervical carcinogenesis: concepts and clinical implications”. J. Pathol., 2006, 208, 152.

[24] Lie A.K., Risberg B., Borge B., Sandstad B., Delabie J., Rimala R. et al.: “DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia”. Gynecol. Oncol., 2005, 97, 908.

[25] Hoppe-Seyler F., Butz K.: “Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53”. J. Virol., 1993, 67, 3111.